http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Cinzia Cavestro,Giorgio Bedogni,Filippo Molinari,Silvia Mandrino,Eugenia Rota,Maria Cristina Frigeri 한국식품영양과학회 2018 Journal of medicinal food Vol.21 No.3
Alpha-lipoic acid (ALA) is known to lower insulin resistance (IR), which is common among migraineurs. To assess the effect of ALA on headache in migraineurs with IR, we performed an exploratory study on a cohort of patients with migraine, followed at our Headache Center. The 32 patients took ALA 400 mg b.i.d. for 6 months in addition to their on-going treatment. The percentage of patients with a reduction of at least 50% of the attacks was 0.53 (confidence interval [95% CI] 0.36–0.70) at 2 months, 0.56 (0.39–0.73) at 4 months, and 0.69 (0.53–0.85) at 6 months. The incidence rate ratio of attacks at 6 months versus baseline was 0.48 (0.43–0.53, P < .001), corresponding to a mean (95% CI) number of attacks of 5 (4–6) versus 11 (10–12). The number of days of treatment in the previous month was 7.7 (6.8–8.7) at baseline, 5.4 (4.6–6.2) at 2 months, 5.3 (4.5–6.1) at 4 months, and 4.3 (3.6–5.0) at 6 months. Baseline and 120-min glucose and insulin and quantitative insulin sensitivity check index (QUICKI) and the Stumvoll index did not change at 6 months versus baseline. This exploratory study shows that the administration of ALA may be associated with a reduction in the number of attacks and the days of treatment in migraineurs with IR. A randomized controlled trial is needed to test this possibility.
Valerio Nobili,Giorgio Bedogni,Benedetta Donati,Anna Alisi,Luca Valenti 한국식품영양과학회 2013 Journal of medicinal food Vol.16 No.10
The aim of this secondary analysis of a randomized controlled trial was to test whether the I148M variant of Patatin-like phospholipase domain-containing protein-3 (PNPLA3) is associated with the response to docosahexaenoic acid (DHA) in children with non-alcoholic fatty liver disease (NAFLD). Sixty children with NAFLD were randomized in equal numbers to DHA 250 mg/day, DHA 500 mg/day or placebo. Coherently with the primary analysis, the probability of more severe steatosis after 24 months of DHA supplementation was 50% lower [95% confidence interval (CI) - 59% to - 42%)] in the combined DHA 250 and 500 mg/day groups versus placebo. The present secondary analysis revealed an independent effect of PNPLA3 status on the response to DHA. In fact, the probability of more severe steatosis was higher (37%, 95% CI 26– 48%) for the PNPLA3M/M versus I/M genotype and lower (- 12%, 95% CI - 21% to - 3%) for the I/I versus I/M genotype (Somers’ D for repeated measures). We conclude that the 148M allele of PNPLA3 is associated with lower response, and the 148I allele with greater response, to DHA supplementation in children with NAFLD.